335 related articles for article (PubMed ID: 21381033)
1. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
2. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.
Alaoui-Jamali MA; Bismar TA; Gupta A; Szarek WA; Su J; Song W; Xu Y; Xu B; Liu G; Vlahakis JZ; Roman G; Jiao J; Schipper HM
Cancer Res; 2009 Oct; 69(20):8017-24. PubMed ID: 19808972
[TBL] [Abstract][Full Text] [Related]
3. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
4. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
5. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
6. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
7. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
8. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
9. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells.
Gueron G; De Siervi A; Ferrando M; Salierno M; De Luca P; Elguero B; Meiss R; Navone N; Vazquez ES
Mol Cancer Res; 2009 Nov; 7(11):1745-55. PubMed ID: 19903769
[TBL] [Abstract][Full Text] [Related]
10. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
11. Heme oxygenase-1 in macrophages controls prostate cancer progression.
Nemeth Z; Li M; Csizmadia E; Döme B; Johansson M; Persson JL; Seth P; Otterbein L; Wegiel B
Oncotarget; 2015 Oct; 6(32):33675-88. PubMed ID: 26418896
[TBL] [Abstract][Full Text] [Related]
12. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
13. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
14. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
15. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
16. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
17. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
18. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
19. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
20. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]